Understanding how specific histone variants help cells respond to DNA damage
Official title: Shaping DNA Damage Response Networks Via Histone H2A Variants
Funded at Emory University · NIH-11056120 · Data updated 2026-11-12
This study is looking at how certain proteins called histone H2A variants help cancer cells fix their DNA when it's damaged, which could lead to better treatments for cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | January 1, 2025 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $378,194 |
| NIH project number | 5R01CA198279-09 |
| Project ID | NIH-11056120 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cancers that involve DNA damage and repair mechanisms.
✕Less likely to help
Patients with non-cancerous conditions or those whose DNA damage responses are not related to histone variants may not benefit from this research.
What this research studies
This research investigates the role of histone H2A variants in the cellular response to DNA damage, particularly in cancer cells. By using advanced biochemical techniques and cell models, the study aims to uncover how these histone variants interact with other proteins to facilitate DNA repair processes. The research focuses on understanding the mechanisms by which these variants influence cellular responses to radiation and specific cancer treatments, potentially leading to improved therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to new approaches in cancer treatment by enhancing the effectiveness of therapies that target DNA repair mechanisms.
How similar studies have gone: Previous research has shown promising results in understanding the role of histone variants in DNA repair, indicating that this approach has potential for significant advancements in cancer treatment.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Miller, Kyle M — Emory University
- Study coordinator: Miller, Kyle M
Related research
Other NIH-funded projects on the same topics.
-
Administrative and Engagement Core for Breast Cancer Breakthrough in Kenya
A national effort in Kenya to speed up how we screen for breast cancer and connect women to treatment, using teamwork across institutions.
-
Collaborative research program to advance patient care
A multi-project research effort at Emory University aims to push forward medical knowledge that could help people with illnesses in the future.
-
Project-003: A multi-partner research program at Emory University
A multi-faceted NIH grant at Emory University aims to advance understanding in a focused area over several years to benefit patients with diseases or conditions connected to the research.
-
Project-002: advancing patient care through coordinated research at Emory
A multi-project NIH grant at Emory aims to translate findings into better care for people with a health condition by coordinating research efforts across teams.
-
Project-006: A Multidisciplinary Emory Initiative to Advance Medical Understanding
A multi-project NIH grant at Emory University aims to push forward medical knowledge in areas that could eventually help patients.
-
Project-005: A multi-component research effort at Emory University
A multi-part NIH grant from Emory University aims to advance understanding in a specific health area over several years with potential patient benefits in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.